149506-79-6

Usage

Uses

As of now, there isn't much information available regarding the specific applications of 4-(dibenzylamino)cyclohexanone. However, given its structural features, it may potentially be used in various industries such as pharmaceuticals, materials science, or chemical research. The following are hypothetical uses based on its chemical structure:
Used in Pharmaceutical Industry:
4-(dibenzylamino)cyclohexanone could be used as an intermediate compound for the synthesis of pharmaceutical drugs, given its amine and cyclohexanone functional groups, which are common in many drug molecules.
Used in Materials Science:
4-(dibenzylamino)cyclohexanone might be employed as a building block for the development of new materials with specific properties, such as improved thermal stability or enhanced solubility in certain solvents.
Used in Chemical Research:
4-(dibenzylamino)cyclohexanone could be utilized in academic or industrial research settings to study its physical and chemical properties, such as melting point, boiling point, solubility, and stability, as well as its potential reactivity with other compounds.

Upstream product

• 4732-69-8 Chloro-oxo-acetic acid 
• 67-68-5 dimethyl sulfoxide 
• 149506-81-0 trans-4-(dibenzylamino)cyclohexanol 
• 100-52-7 benzaldehyde 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 177906-47-7 trans-4-Hydroxycyclohexyldibenzylamine 
• 27489-62-9 trans-4-aminocyclohexan-1-ol 
• 103-49-1 dibenzylamine 
• 6850-65-3 p-hydroxycyclohexylamine 
• 100-39-0 benzyl bromide 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 100-46-9 benzylamine 
• 79-37-8 oxalyl dichloride 
• 168893-04-7 N,N-dibenzyl-1,4-dioxaspiro[4.5]decan-8-amine 

Downstream Products

• 883195-41-3 4-dibenzylamino-cyclohexanone oxime 
• 755039-85-1 trans-dibenzyl-[4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-amine 
• 755039-86-2 cis-dibenzyl-[4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-amine 
• 755039-80-6 trans-dibenzyl-(4-morpholin-4-yl-cyclohexyl)-amine 
• 755039-79-3 cis-dibenzyl-(4-morpholin-4-yl-cyclohexyl)-amine 
• 31059-08-2 1-(1H-imidazol-1-yl)-2-methoxyethanone 
• 1202411-99-1 4-dibenzylamino-1-trifluormethylcycohexanol 
• 1202411-57-1 dibenzyl-(1-oxa-spiro[2.5]oct-6-yl)-amine 
• 1119283-62-3 (trans)-N,N-dibenzyl-4-(4-methylpiperazin-1-yl)cyclohexanamine 
• 883195-12-8 C₂₅H₃₅N₃ 
• 1119283-64-5 C₁₁H₂₃N₃ 
• 1119283-66-7 C₁₆H₃₁N₃O₂ 
• 1119283-68-9 C₁₂H₂₅N₃ 
• 1119284-16-0 C₁₃H₂₅N₃O 

Relevant academic research and scientific papers

CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions.

NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF

The present invention relates to compounds of formula (I), or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein said compound of formula (I) comprises at least one covalently bound -ONO2 or -ONO moiety and at most four covalently bound -ONO2 or -ONO moieties, and wherein AR, R1, X, R3 and R4 are as defined in claim 1; and pharmaceutical compositions thereof, and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-human mammal.

TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS

This invention is to methods for treating disorders involving abnormal cellular proliferation that have developed resistance to a selective CDK4/6 inhibitor.

Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β

We disclose a novel class of 6-Amino-Tetrahydroquinazoline derivatives that inhibit human topoisomerase II (topoII), a validated target of anticancer drugs. In contrast to topoII-Targeted drugs currently in clinical use, these compounds do not act as topo

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION

This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

4-AMINO-2-PYRIDO-BICYCLIC PYRIMIDINES AND USE THEREOF AS TOPOISOMERASE II INHIBITORS

The present invention concerns 4-amino-2-pyrido-bicyclic pyrimidines as type II topoisomerase inhibitors and use thereof as medicaments especially in the treatment of cancer. The invention also provides a method for the manufacture of 4- amino-2-pyrido bicyclic pyrimidines.

1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS

A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS

This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

Synthesis of dibenzylamino-1-methylcyclohexanol and dibenzylamino-1-trifluoromethylcyclohexanol isomers

The isomers of dibenzylamino-1-methylcyclohexan-1-ol and dibenzylamino-1-trifluoromethylcyclohexan-1-ol have been prepared. The stereochemistry of these compounds was unequivocally assigned through a combination of NMR spectroscopy and single crystal X-ra

INDOLE DERIVATIVE

The present invention provides an indole derivative having a melanin-concentrating hormone receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.